Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.70 |
| ▸ | HTR2A | P28223 | 6/20 | 0.70 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 2/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 2/20 | 0.60 |
| ▸ | HTR6 | P50406 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9596033 | 0.99 | DRD2 (0.69) | DRD2HTR2AMCHR1ACHESLC6A4 | |
| SCHEMBL793140 | 0.98 | DRD2 (0.70) | DRD2HTR2AMCHR1ACHESLC6A4 | |
| SCHEMBL1544931 | 0.94 | ACHE (0.71) | DRD2HTR2AMCHR1ACHESLC6A4 | |
| Hydrochloric Acid SCHEMBL1545126 | 0.93 | ACHE (0.70) | DRD2HTR2AMCHR1ACHESLC6A4 | |
| SCHEMBL1545401 | 0.88 | ACHE (0.71) | DRD2HTR2AMCHR1ACHESLC6A4 | |
| SCHEMBL1545289 | 0.88 | ACHE (0.65) | DRD2HTR2AMCHR1ACHESLC6A4 | |
| SCHEMBL1545965 | 0.87 | ACHE (0.67) | DRD2HTR2AMCHR1ACHESLC6A4 | |
| Fumaric Acid SCHEMBL1545814 | 0.87 | ACHE (0.62) | DRD2HTR2AMCHR1ACHESLC6A4 | |
| Fumaric Acid SCHEMBL1545815 | 0.87 | ACHE (0.62) | DRD2HTR2AMCHR1ACHESLC6A4 | |
| Hydrochloric Acid SCHEMBL1545683 | 0.87 | ACHE (0.64) | DRD2HTR2AMCHR1ACHESLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1993016073-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | claimed |
| US-9120767-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z.O.O. (PL) | 2015-09-01 | — | — | US | disclosed |
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2014-11-13 | — | — | US | disclosed |
| US-8822517-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z O.O. (PL) | 2014-09-02 | — | — | US | disclosed |
| EP-2616440-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | Adamed sp. z o.o. (PL) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z.O.O. (PL) | 2013-07-04 | — | — | US | disclosed |
| WO-2012035123-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2012-03-22 | — | — | WO | disclosed |
| EP-2311824-A1 | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics | Aventis Pharmaceuticals Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-0963984-B1 | Heteroarylpiperidines and piperazines and their use as antipsychotics and analgetics | AVENTIS PHARMA INC (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-0959076-B1 | Heteroarylperidines and piperazines and their use as antipsychotics and analgetics | AVENTIS PHARMA INC (US) | 2007-03-07 | — | — | EP | disclosed |
| US-5554614-A | TREATMENT OF PSYCHOLOGICAL DISORDERS, PSYCHOSES; ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1996-09-10 | — | — | US | disclosed |
| US-5552414-A | 1-(1H-indolyloxyalkyl)-4-(heteroaryl) piperidines and related compounds useful as antipsychotics and analgesics | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| US-5550130-A | ANTIPSYCHOTIC AGENTS, ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1995011680-A1 | HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| EP-0625978-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-30 | — | — | EP | disclosed |
| US-5364866-A | Side effect reduction | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0612318-A1 | HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-08-31 | — | — | EP | disclosed |
| WO-1993016073-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
| EP-0542136-A1 | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-05-19 | — | — | EP | disclosed |
| WO-1993009102-A1 | HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | DRD2 3216/4885HTR2A 1150/4885MCHR1 2160/4885 |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | DRD2 3216/4885HTR2A 1150/4885MCHR1 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.